RGEN vs. EXEL, NBIX, HALO, DNLI, ADPT, BIIB, QGEN, PCVX, RVMD, and CRSP
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Exelixis (EXEL), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Exelixis currently has a consensus target price of $26.29, suggesting a potential upside of 10.91%. Repligen has a consensus target price of $196.70, suggesting a potential upside of 18.08%. Given Exelixis' stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Exelixis.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 2.9% of Exelixis shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Exelixis has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Exelixis has a net margin of 11.35% compared to Exelixis' net margin of 6.51%. Repligen's return on equity of 8.57% beat Exelixis' return on equity.
In the previous week, Exelixis had 10 more articles in the media than Repligen. MarketBeat recorded 14 mentions for Exelixis and 4 mentions for Repligen. Exelixis' average media sentiment score of 1.01 beat Repligen's score of 0.58 indicating that Repligen is being referred to more favorably in the news media.
Exelixis has higher revenue and earnings than Repligen. Exelixis is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Exelixis received 174 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 68.09% of users gave Exelixis an outperform vote while only 68.03% of users gave Repligen an outperform vote.
Summary
Exelixis beats Repligen on 10 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
